223 related articles for article (PubMed ID: 22748832)
21. Micro- and nanotechnology approaches to improve Parkinson's disease therapy.
Torres-Ortega PV; Saludas L; Hanafy AS; Garbayo E; Blanco-Prieto MJ
J Control Release; 2019 Feb; 295():201-213. PubMed ID: 30579984
[TBL] [Abstract][Full Text] [Related]
22. The development of encapsulated cell technologies as therapies for neurological and sensory diseases.
Zanin MP; Pettingill LN; Harvey AR; Emerich DF; Thanos CG; Shepherd RK
J Control Release; 2012 May; 160(1):3-13. PubMed ID: 22285549
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery.
Nafissi N; Foldvari M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016; 8(2):240-54. PubMed ID: 26306832
[TBL] [Abstract][Full Text] [Related]
24. Advances in the treatment of neurodegenerative disorders employing nanoparticles.
Spuch C; Saida O; Navarro C
Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):2-18. PubMed ID: 22272933
[TBL] [Abstract][Full Text] [Related]
25. The neuroprotective effect of focused ultrasound: New perspectives on an old tool.
Yulug B; Hanoglu L; Kilic E
Brain Res Bull; 2017 May; 131():199-206. PubMed ID: 28458041
[TBL] [Abstract][Full Text] [Related]
26. Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease.
O'Neill MJ; Messenger MJ; Lakics V; Murray TK; Karran EH; Szekeres PG; Nisenbaum ES; Merchant KM
Int Rev Neurobiol; 2007; 77():179-217. PubMed ID: 17178475
[No Abstract] [Full Text] [Related]
27. SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases.
Porzner M; Müller T; Seufferlein T
Expert Opin Investig Drugs; 2009 Nov; 18(11):1765-72. PubMed ID: 19814656
[TBL] [Abstract][Full Text] [Related]
28. Targeting JNK3 for the treatment of neurodegenerative disorders.
Resnick L; Fennell M
Drug Discov Today; 2004 Nov; 9(21):932-9. PubMed ID: 15501728
[TBL] [Abstract][Full Text] [Related]
29. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
Chen JF; Chern Y
Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
[TBL] [Abstract][Full Text] [Related]
30. Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?
Kordower JH; Isacson O; Leventhal L; Emerich DF
Prog Brain Res; 2000; 127():414-30. PubMed ID: 11142039
[No Abstract] [Full Text] [Related]
31. Neuroprotective effect of neurotrophic factors in experimental models of neurodegenerative disorders.
Alberch J
Methods Find Exp Clin Pharmacol; 1997; 19 Suppl A():63-4. PubMed ID: 9403862
[No Abstract] [Full Text] [Related]
32. Delivery of therapeutic molecules into the CNS.
Emborg ME; Kordower JH
Prog Brain Res; 2000; 128():323-32. PubMed ID: 11105691
[No Abstract] [Full Text] [Related]
33. [Progress in treatment of retinitis pigmentosa by neurotrophic factors].
Zhang X; Li GL
Zhonghua Yan Ke Za Zhi; 2009 Sep; 45(9):855-9. PubMed ID: 20137292
[TBL] [Abstract][Full Text] [Related]
34. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
Voutilainen MH; Bäck S; Peränen J; Lindholm P; Raasmaja A; Männistö PT; Saarma M; Tuominen RK
Exp Neurol; 2011 Mar; 228(1):99-108. PubMed ID: 21185834
[TBL] [Abstract][Full Text] [Related]
35. Neurotrophin delivery using nanotechnology.
Angelova A; Angelov B; Drechsler M; Lesieur S
Drug Discov Today; 2013 Dec; 18(23-24):1263-71. PubMed ID: 23891881
[TBL] [Abstract][Full Text] [Related]
36. Pathologically activated therapeutics for neuroprotection.
Lipton SA
Nat Rev Neurosci; 2007 Oct; 8(10):803-8. PubMed ID: 17882256
[TBL] [Abstract][Full Text] [Related]
37. The role of the blood brain barrier in neurodegenerative disorders and their treatment.
Palmer AM
J Alzheimers Dis; 2011; 24(4):643-56. PubMed ID: 21460432
[TBL] [Abstract][Full Text] [Related]
38. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.
Wang Q; Yan J; Chen X; Li J; Yang Y; Weng J; Deng C; Yenari MA
Exp Neurol; 2011 Jul; 230(1):27-34. PubMed ID: 20406638
[TBL] [Abstract][Full Text] [Related]
39. Advances in the treatment of neurodegenerative disorders employing nanotechnology.
Modi G; Pillay V; Choonara YE
Ann N Y Acad Sci; 2010 Jan; 1184():154-72. PubMed ID: 20146696
[TBL] [Abstract][Full Text] [Related]
40. Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives.
El Ouaamari Y; Van den Bos J; Willekens B; Cools N; Wens I
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
